MRI Contrast Media Market Report 2026

The mri contrast media market size has grown strongly in recent years. It will grow from $1.66 billion in 2025 to $1.76 billion in 2026 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to increasing diagnostic imaging demand, reliance on gadolinium agents, limited safety data availability, gradual equipment modernization, rising neurological disorder incidence.

The mri contrast media market size is expected to see strong growth in the next few years. It will grow to $2.15 billion in 2030 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to expansion of cancer screening programs, adoption of novel mri contrast formulations, growth in outpatient imaging centers, rising investments in radiology r&d, increasing focus on safer contrast compositions. Major trends in the forecast period include increasing use of gadolinium-free contrast agents, rising adoption of nano-based contrast materials, expansion of contrast media safety monitoring protocols, growth in mri utilization for chronic disease diagnosis, development of organ-specific and targeted agents.

The rising incidence of cancer is expected to drive the growth of the MRI contrast media market in the coming years. Cancer prevalence is influenced by demographic, lifestyle, environmental, genetic, and healthcare-related factors. MRI contrast agents containing gadolinium-based compounds improve imaging by altering tissue magnetic properties, helping detect, size, and characterize tumors, and assess their invasion into surrounding tissues. For instance, in January 2024, according to the American Cancer Society, a US-based nonprofit organization, the United States is projected to report 2,001,140 new cancer cases and 611,720 cancer deaths in 2024, up from 1,958,310 cases and 609,820 deaths in 2023. Therefore, the rising cancer incidence is propelling the MRI contrast media market.

Major companies in the MRI contrast media market are focusing on innovative products such as macrocyclic gadolinium-based contrast agents (GBCA) to improve diagnostic accuracy and safety in MRI procedures. A macrocyclic GBCA is a contrast agent used in MRI that provides high stability and enhanced imaging performance. For example, in February 2023, Guerbet, a France-based MRI contrast media provider, launched Elucirem (gadopiclenol) injection. This agent features a highly stable macrocyclic structure with the highest relaxivity in its class, enabling superior detection and visualization of lesions with abnormal vascularity across the central nervous system - including the brain, spine, and associated tissues - as well as regions of the body such as the head and neck, thorax, abdomen, pelvis, and musculoskeletal system.

In March 2023, Bracco Imaging S.p.A., an Italy-based healthcare company, acquired the remaining 49% stake in Bracco-Eisai Co. Ltd., a Japan-based MRI contrast media provider, for an undisclosed amount. The acquisition aims to strengthen Bracco Imaging’s ability to respond quickly to evolving healthcare needs and deliver sustainable benefits to patients through its expanded product offerings.

Major companies operating in the mri contrast media market are Bayer AG, GE Healthcare Technologies Inc., Bracco S.p.A., Guerbet LLC, Lantheus Medical Imaging Inc., Fujifilm Holdings Corporation, Spago Nanomedical AB, Fresenius Kabi AG, Curium Pharma, Miltenyi Biotec B.V. & Co. KG, Polarean Inc., BioPAL Inc., Jiangsu Hengrui Pharmaceutical Co. Ltd., Trivitron Healthcare, Beijing Beilu Pharmaceuticals Company Limited, Taejoon Pharm Co. Ltd., Mediso USA LLC, Nano Therapeutics Pvt. Ltd., Eisai Co. Ltd., Daiichi Sankyo Company Limited, Maruishi Pharmaceutical Co. Ltd., Jodas Expoim Pvt Ltd, Lumiphore Inc., Naviscan Inc.

North America was the largest region in the MRI contrast media market in 2025. The regions covered in the mri contrast media market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mri contrast media market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs in the MRI contrast media market have raised the cost of importing raw materials, specialized chemical compounds, and imaging consumables, particularly affecting hospitals and diagnostic centers in regions dependent on international suppliers. These tariffs contribute to higher procedure costs and potential delays in supply availability. However, they have also encouraged regional manufacturing and innovation in contrast formulations, which could reduce long-term dependency on global supply chains and improve market resilience.

The mri contrast media market research report is one of a series of new reports that provides mri contrast media market statistics, including mri contrast media industry global market size, regional shares, competitors with a mri contrast media market share, detailed mri contrast media market segments, market trends and opportunities, and any further data you may need to thrive in the mri contrast media industry. This mri contrast media market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

MRI contrast media are substances used in magnetic resonance imaging (MRI) to improve the visibility of internal body structures. These agents enhance image contrast by altering the magnetic properties of tissues, allowing for clearer and more detailed imaging results.

The main MRI contrast media products include extracellular contrast agents, blood-pool agents, and hepatobiliary agents. Extracellular contrast agents are specifically used to enhance the visibility of internal structures during MRI scans. They are applied in the diagnosis and assessment of neurological disorders, musculoskeletal disorders, cardiovascular conditions, cancer detection, and other medical applications, serving end users such as hospitals, diagnostic and imaging centers, research institutes, and others.

The MRI contrast media market consists of sales of gadopentetate dimeglumine (Gd-DTPA), gadodiamide, diatrizoate, and gadoversetamide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.